Wexford Capital’s Avanos Medical AVNS Stock Holding History

Wexford Capital’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6,099	Closed	-$70.5K	–	392
2025 Q3	$70.5K	Buy	+6,099	New	+$71.4K	0.01%	267

Other funds holding AVNS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wexford Capital's AVNS Position: Q4 2025 in Review

Wexford Capital sold out of Avanos Medical (AVNS) in Q4 2025, closing a stake of 6,099 shares — an estimated $70.5K sold.

Wexford Capital first reported a position in AVNS in Q3 2025 and held it in 1 quarter. The position peaked at $70.5K in Q3 2025. 274 funds tracked by Wall St. Rank hold AVNS as of Q4 2025.

Wexford Capital reported no remaining Avanos Medical position as of Q4 2025 after selling out during the quarter.
Wexford Capital sold 6,099 Avanos Medical shares in Q4 2025, an estimated $70.5K.
Wexford Capital first reported a position in Avanos Medical in Q3 2025 and held it in 1 quarter.
Wexford Capital's Avanos Medical position peaked at $70.5K in Q3 2025.
274 funds tracked by Wall St. Rank held Avanos Medical as of Q4 2025.

Based on Wexford Capital's 13F filing for Q4 2025, filed 13 Feb 2026.